Education
About Us
Working with TipRanks
Follow Us
Baker Bros. Advisors Lp Insider Profile
102 Followers
Baker Bros. Advisors Lp, Ten Percent Owner at BioCryst, holds 8.34M shares in BeiGene (Ticker: ONC), holds 10.00M shares in Bicycle Therapeutics (Ticker: BCYC), holds 3.76M shares in IGM Biosciences (Ticker: IGMS). Most recently, Baker Bros. Advisors Lp Sold ― shares of BeiGene on Feb 28, 2025 for an estimated value of 190.54M.
Baker Bros. Advisors Lp BioCryst (BCRX)Ten Percent Owner
BioCryst (BCRX)
Ten Percent Owner
Ranked #219 out of 100,956 Corporate Insiders
Profitable Transactions
49 out of 90 Profitable Transactions
Average Return
+28.20%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Baker Bros. Advisors Lp's holdings
Insider Roles
Roles that Baker Bros. Advisors Lp holds in companies
Most Profitable Insider Trade
Stock:
Invitae
(NVTAQ)
(NVTAQ)
Rating:Informative Buy
Date:Mar 29, 2018 - Mar 29, 2019
Return:+399.30%
The most profitable trade made by Baker Bros. Advisors Lp
Baker Bros. Advisors Lp's Trading History
BioCryst
Aug 16, 2016
Ten Percent Owner
Informative Sell
20.25M
$115.84M
Bellicum Pharmaceuticals
Nov 24, 2023
―
Uninformative Buy
―
$160.49K
BeiGene
Feb 28, 2025
Director
Informative Sell
190.54M
$2.06B
Aceragen
Jul 03, 2019
―
Uninformative Buy
15.47K
$1.65M
Alexion Pharmaceuticals
May 18, 2020
―
Uninformative Buy
―
$1.47B
Kiniksa Pharmaceuticals
Oct 08, 2024
Director
Uninformative Buy
―
$59.37M
Hookipa Pharma
Apr 23, 2019
Former 10% owner
Informative Buy
12.50M
$1.04M
Kodiak Sciences
Jun 06, 2022
Director, Ten Percent Owner
Informative Buy
4.45M
$57.80M
IGM Biosciences
Jan 03, 2025
Director, Ten Percent Owner
Uninformative Buy
―
$4.97M
Atreca
Oct 23, 2023
―
Informative Sell
109.90K
$267.40K
Zymeworks
―
Director
―
―
Prelude Therapeutics
Jan 29, 2021
Director, Ten Percent Owner
Uninformative Buy
133.33K
$6.81M
Spyre Therapeutics
―
Director
―
―
Talis Biomedical
Nov 19, 2021
Director, Ten Percent Owner
Informative Buy
218.00K
$12.20M
TScan Therapeutics
May 12, 2022
Director
Informative Buy
2.56M
$5.01M
Entrada Therapeutics Inc
Jun 06, 2022
Ten Percent Owner
Informative Buy
260.68K
$48.48M
DBV Technologies SA - American
Jun 13, 2022
Director, Ten Percent Owner
Uninformative Buy
―
$121.87M
Madrigal Pharmaceuticals
Jun 27, 2024
Director
Uninformative Buy
―
$594.82M
vTv Therapeutics
Mar 07, 2024
Director
Uninformative Sell
―
$1.37M
Kymera Therapeutics
Aug 22, 2024
Director
Informative Buy
46.41
$197.21M
Bicycle Therapeutics
Jan 06, 2025
Director, Ten Percent Owner
Uninformative Buy
―
$102.30M
Immunocore Holdings
―
Director
―
―
Kala Pharmaceuticals
Dec 31, 2024
Ten Percent Owner
Informative Buy
2.00M
$7.64M
Replimune Group
―
Director, Ten Percent Owner
―
―
Mirati Therapeutics
Nov 13, 2017
―
Informative Buy
2.20M
$2.13M
Neurogene
Oct 10, 2023
Director, Former 10% Owner
Uninformative Buy
―
$7.84M
Invitae
Mar 29, 2018
―
Informative Buy
5.00M
$83.09K
ACADIA Pharmaceuticals
May 31, 2024
Director, Ten Percent Owner
Uninformative Buy
―
$694.59M
Xoma
Jul 23, 2015
Former 10% owner
Informative Sell
11.99M
$1.98M
Genomic Health
Oct 03, 2019
―
Uninformative Buy
124.47K
$484.81M
Incyte
Jan 03, 2025
Director, Ten Percent Owner
Uninformative Buy
―
$2.04B
Seagen
Jun 02, 2023
―
Uninformative Buy
―
$9.84B
Synageva
―
―
―
―
List of latest transactions for each holding click on a transaction to see Baker Bros. Advisors Lp's performance on stock
You May Also Like
Baker Bros. Advisors Lp insider profile FAQ
What is the percentage of profitable transactions made by Baker Bros. Advisors Lp?
The percentage of profitable transactions made by Baker Bros. Advisors Lp is 54%.
What is the average return per transaction made by Baker Bros. Advisors Lp?
The average return per transaction made by Baker Bros. Advisors Lp is 28.20%.
What stocks does Baker Bros. Advisors Lp hold?
Baker Bros. Advisors Lp holds: BCRX, BLCM, ONC, ACGN, ALXN, KNSA, HOOK, KOD, IGMS, BCEL, ZYME, PRLD, SYRE, TLIS, TCRX, TRDA, DBVT, MDGL, VTVT, KYMR, BCYC, IMCR, KALA, REPL, MRTX, NGNE, NVTAQ, ACAD, XOMA, GHDX, INCY, SGEN, GEVA stocks.
What was Baker Bros. Advisors Lp’s latest transaction?
Baker Bros. Advisors Lp latest transaction was an Informative Sell of $190.54M.
What was Baker Bros. Advisors Lp's most profitable transaction?
Baker Bros. Advisors Lp’s most profitable transaction was an Informative Buy of NVTAQ stock on March 29, 2018. The return on the trade was 399.30%.
What is Baker Bros. Advisors Lp's role in BioCryst?
Baker Bros. Advisors Lp's role in BioCryst is Ten Percent Owner.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.